Trusted Resources: Education
Scientific literature and patient education texts
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
source: Frontiers in Neurology
year: 2021
authors: Kotulska K, Fattal-Valevski A, Haberlova J
summary/abstract:Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by deletion or mutation of the gene. It is characterized by a progressive loss of motor neurons resulting in muscle weakness. The disease affects 1 in 11,000 live births and before the era of treatment SMA was a leading genetic cause of mortality in infants. Recently, disease modifying therapies have been introduced in clinical practice. They include intrathecal and oral antisense oligonucleotides binding to pre-mRNA of gene and increasing the translation of fully functional SMN protein as well as gene replacement therapy.
Onasemnogene abeparvovec uses the adeno-associated virus 9 (AAV9) vector to deliver the gene. Phase 1 and phase 3 clinical trials showed that a single administration of onasemnogene abeparvovec resulted in improvement of motor functions in the majority of infants with SMA. Currently, phase 3 trials in SMA1 and SMA2 patients, as well as presymptomatic infants diagnosed with SMA, are ongoing. The drug was approved for medical use in the US in 2019, and in Japan and the European Union in 2020. Thus, first real-world data on efficacy and safety of onasemnogene abeparvovec in SMA patients are available.
organization: The Children's Memorial Health Institute, Poland; Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel; School of Medicine Charles University, CzechiaDOI: 10.3389/fneur.2021.726468
read more
Related Content
-
Dynamic Balance in Spinal and Bulbar Muscular Atrophy: Relationship Between Strength and Performance of Forward Lung...Introduction: Spinal and bulbar muscular...
-
Carrier Screening for Genetic ConditionsCarrier screening is a term used to desc...
-
Magnetic Resonance Reveals Mitochondrial Dysfunction and Muscle Remodelling in Spinal Muscular AtrophyGenetic therapy has changed the prognosi...
-
Biogen Exercises Option With Ionis to Develop and Commercialize Investigational ASO for SMABiogen, Inc. and Ionis Pharmaceuticals, ...
-
Why Some Drugs Cost $2.1 Million per Dose and how one Company Plans to Change ThisWith a cost of $2.1 million for a one-do...
-
Axonal Excitability Changes in Children With Spinal Muscular Atrophy Treated With NusinersenSpinal muscular atrophy (SMA) is associa...
-
Understanding Spinal Muscular Atrophy (SMA)https://www.youtube.com/watch?v=5mI_ZsWk...